Comparison of neutralizing dengue virus B cell epitopes and protective T cell epitopes with those in three main dengue virus vaccines

Full metadata record
DC FieldValueLanguage
dc.contributorLab. Parasitologiapt_BR
dc.contributor.authorPinheiro, Josilene Ramospt_BR
dc.contributor.authorReis, Esther Camilo dospt_BR
dc.contributor.authorSouza, Rayane da Silva Oliveirapt_BR
dc.contributor.authorRocha, Ana Luíza Silvapt_BR
dc.contributor.authorSuesdek, Lincolnpt_BR
dc.contributor.authorAzevedo, Vascopt_BR
dc.contributor.authorTiwari, Sandeeppt_BR
dc.contributor.authorRocha, Beatriz Gonçalves Silvapt_BR
dc.contributor.authorBirbrair, Alexanderpt_BR
dc.contributor.authorMéndez, Erick Carvalhopt_BR
dc.contributor.authorLuiz, Wilson Barrospt_BR
dc.contributor.authorAmorim, Jaime Henriquept_BR
dc.identifier.citationPinheiro JR, Reis EC, Souza RSO, Rocha ALS, Suesdek L, Azevedo V, et al. Comparison of neutralizing dengue virus B cell epitopes and protective T cell epitopes with those in three main dengue virus vaccines. Front. Immunol.. 2021 Aug;12:715136. doi:10.3389/fimmu.2021.715136.pt_BR
dc.description.abstractThe four serotypes of Dengue virus (DENV1-4) are arboviruses (arthropod-borne viruses) that belong to the Flavivirus genus, Flaviviridae family. They are the causative agents of an infectious disease called dengue, an important global public health problem with significant social-economic impact. Thus, the development of safe and effective dengue vaccines is a priority according to the World Health Organization. Only one anti-dengue vaccine has already been licensed in endemic countries and two formulations are under phase III clinical trials. In this study, we aimed to compare the main anti-dengue virus vaccines, DENGVAXIA®, LAV-TDV, and TAK-003, regarding their antigens and potential to protect. We studied the conservation of both, B and T cell epitopes involved in immunological control of DENV infection along with vaccine viruses and viral isolates. In addition, we assessed the population coverage of epitope sets contained in each vaccine formulation with regard to different human populations. As main results, we found that all three vaccines contain the main B cell epitopes involved in viral neutralization. Similarly, LAV-TDV and TAK-003 contain most of T cell epitopes involved in immunological protection, a finding not observed in DENGVAXIA®, which explains main limitations of the only licensed dengue vaccine. In summary, the levels of presence and absence of epitopes that are target for protective immune response in the three main anti-dengue virus vaccines are shown in this study. Our results suggest that investing in vaccines that contain the majority of epitopes involved in protective immunity (cellular and humoral arms) is an important issue to be considered.pt_BR
dc.description.sponsorshipInstituto Serrapilheirapt_BR
dc.description.sponsorship(CONSID) Consórcio Multifinalitário do Oeste da Bahiapt_BR
dc.description.sponsorship(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.relation.ispartofFrontiers in Immunologypt_BR
dc.rightsOpen accesspt_BR
dc.titleComparison of neutralizing dengue virus B cell epitopes and protective T cell epitopes with those in three main dengue virus vaccinespt_BR
dc.rights.licenseCC BYpt_BR
dc.contributor.external(UFOB) Universidade Federal do Oeste da Bahiapt_BR
dc.contributor.external(UESC) Universidade Estadual de Santa Cruzpt_BR
dc.contributor.external(UFMG) Universidade Federal de Minas Geraispt_BR
dc.subject.keywordimmunization programspt_BR
dc.relation.ispartofabbreviatedFront. Immunol.pt_BR
dc.identifier.citationabntv. 12, 715136, ago. 2021pt_BR
dc.identifier.citationvancouver2021 Aug;12:715136pt_BR
dc.contributor.butantanSuesdek, Lincoln|:Pesquisador|:Lab. Parasitologiapt_BR
dc.sponsorship.butantanInstituto Serrapilheira¦¦1708-15285pt_BR
dc.sponsorship.butantanConsórcio Multifinalitário do Oeste da Bahia (CONSID)¦¦001pt_BR
dc.sponsorship.butantanConsórcio Multifinalitário do Oeste da Bahia (CONSID)¦¦27968pt_BR
dc.sponsorship.butantanConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)¦¦pt_BR
item.fulltextCom Texto completo-
Appears in Collections:Artigos de periódicos

Files in This Item:

Size: 2.53 MB
Format: Adobe PDF
Show simple item record

This item is licensed under a Creative Commons License Creative Commons